$4.77 Billion is the total value of DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s 127 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| New | XILIO THERAPEUTICS INC | $33,739,000 | – | 2,154,061 | +100.0% | 0.71% | – | |
| New | THE ONCOLOGY INSTITUTE INC | $32,137,000 | – | 3,296,107 | +100.0% | 0.67% | – | |
| ESPR | New | ESPERION THERAPEUTICS INC NE | $25,000,000 | – | 5,000,000 | +100.0% | 0.52% | – |
| FIGS | New | FIGS INCcl a | $22,867,000 | – | 829,707 | +100.0% | 0.48% | – |
| BLU | New | BELLUS HEALTH INC NEW | $19,714,000 | – | 2,449,000 | +100.0% | 0.41% | – |
| NVRO | New | NEVRO CORP | $17,511,000 | – | 216,000 | +100.0% | 0.37% | – |
| BBIO | New | BRIDGEBIO PHARMA INCcall | $16,680,000 | – | 1,000,000 | +100.0% | 0.35% | – |
| APLS | New | APELLIS PHARMACEUTICALS INC | $16,227,000 | – | 343,213 | +100.0% | 0.34% | – |
| APEN | New | APOLLO ENDOSURGERY INC | $14,753,000 | – | 1,750,000 | +100.0% | 0.31% | – |
| MRUS | New | MERUS N V | $13,897,000 | – | 437,000 | +100.0% | 0.29% | – |
| MRTX | New | MIRATI THERAPEUTICS INC | $12,909,000 | – | 88,000 | +100.0% | 0.27% | – |
| SRPT | New | SAREPTA THERAPEUTICS INC | $12,697,000 | – | 141,000 | +100.0% | 0.27% | – |
| New | LIANBIOsponsored ads | $10,982,000 | – | 1,782,747 | +100.0% | 0.23% | – | |
| SRSA | New | SARISSA CAPITAL ACQUISITN COcl a | $9,790,000 | – | 999,999 | +100.0% | 0.20% | – |
| EUCR | New | EUCRATES BIOMEDICAL ACQU COR | $9,760,000 | – | 999,999 | +100.0% | 0.20% | – |
| New | WEAVE COMMUNICATIONS INC | $8,418,000 | – | 554,519 | +100.0% | 0.18% | – | |
| New | GUARDANT HEALTH INCnote 11/1 | $8,053,000 | – | 8,000,000 | +100.0% | 0.17% | – | |
| TMPM | New | TURMERIC ACQUISITION CORPcl a | $7,365,000 | – | 750,000 | +100.0% | 0.15% | – |
| New | HYPERFINE INC | $7,250,000 | – | 1,000,000 | +100.0% | 0.15% | – | |
| New | BENEFITFOCUS INCnote 1.250%12/1 | $6,229,000 | – | 6,500,000 | +100.0% | 0.13% | – | |
| New | PYXIS ONCOLOGY INC | $3,420,000 | – | 311,754 | +100.0% | 0.07% | – | |
| New | ROIVANT SCIENCES LTD*w exp 09/30/202 | $2,047,000 | – | 1,000,000 | +100.0% | 0.04% | – | |
| GKOS | New | GLAUKOS CORPcall | $2,009,000 | – | 45,200 | +100.0% | 0.04% | – |
| New | THE ONCOLOGY INSTITUTE INC*w exp 11/15/202 | $863,000 | – | 1,250,000 | +100.0% | 0.02% | – | |
| TMPMW | New | TURMERIC ACQUISITION CORP*w exp 10/08/202 | $170,000 | – | 250,000 | +100.0% | 0.00% | – |
| EUCRW | New | EUCRATES BIOMEDICAL ACQU COR*w exp 10/23/202 | $193,000 | – | 333,333 | +100.0% | 0.00% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AERIE PHARMACEUTICALS INC | 36 | Q3 2022 | 3.6% |
| CENTENE CORP DEL | 30 | Q3 2023 | 3.0% |
| BIOCRYST PHARMACEUTICALS INC | 29 | Q3 2023 | 2.2% |
| MOLINA HEALTHCARE INC | 26 | Q3 2022 | 1.7% |
| EHEALTH INC | 25 | Q3 2020 | 2.0% |
| INTERCEPT PHARMACEUTICALS IN | 24 | Q1 2023 | 2.2% |
| MYLAN NV | 23 | Q3 2020 | 6.2% |
| PORTOLA PHARMACEUTICALS INC | 23 | Q1 2019 | 6.0% |
| BROOKDALE SR LIVING INC | 23 | Q3 2023 | 2.2% |
| ALIMERA SCIENCES INC | 23 | Q3 2019 | 0.8% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| DA32 Life Science Tech Acquisition Corp. | August 01, 2023 | 5,145,000 | 91.1% |
| CareMax, Inc. | March 13, 2023 | 18,691,423 | 16.4% |
| CareMax, Inc. | June 02, 2022 | 18,691,423 | 20.7% |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 3 | 2024-03-19 |
| 4 | 2024-03-19 |
| 4 | 2024-03-12 |
| 3 | 2024-03-08 |
| 4 | 2024-02-16 |
| 13F-HR | 2024-02-14 |
| 4 | 2024-02-08 |
| 3 | 2024-02-01 |
| 4 | 2023-11-21 |
| 13F-HR | 2023-11-14 |
View DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C)'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.